Antipsychotic Comparison Tool
Compare Antipsychotics
Select medications to compare and see their key characteristics side-by-side. This tool helps you understand the trade-offs between different antipsychotics based on clinical data.
Choose medications to compare
Sort results by
Comparison Results
| Medication | Dosage (typical daily) |
Efficacy (1-5) |
Weight Gain Risk |
Metabolic Risk | EPS Risk | Annual NHS Cost (£) |
|---|
Key Takeaways
Select medications to see a comparison.
If you’re weighing Geodon against other options, here’s what matters most: how well it controls symptoms, the side‑effect profile, dosing convenience, drug interactions and price.
What is Geodon (Ziprasidone)?
Geodon is the brand name for ziprasidone, an atypical antipsychotic approved for schizophrenia and bipolar mania. It works by balancing dopamine and serotonin activity in the brain, which helps reduce hallucinations, delusions and mood swings. First launched in the US in 2001, Geodon gained a foothold in the UK after NHS agreements in 2007.
Key criteria for comparing antipsychotics
When you line up Geodon with alternatives, clinicians and patients usually focus on these six factors:
- Efficacy: How reliably the drug reduces core psychotic symptoms.
- Weight gain & metabolic risk: Whether the medication drives weight, cholesterol or blood‑sugar changes.
- Extrapyramidal symptoms (EPS): Tremor, rigidity or restlessness.
- Sedation & daytime sleepiness: Impacts on work or study.
- Drug‑interaction profile: Enzyme pathways that may clash with other prescriptions.
- Cost & formulary status: NHS prescribing limits and patient out‑of‑pocket expenses.
Major alternatives to Geodon
Below are the most frequently prescribed antipsychotics that sit in the same therapeutic class.
- Risperidone - a second‑generation drug known for strong efficacy but a modest risk of prolactin elevation.
- Olanzapine - praised for rapid symptom control; notorious for weight gain and metabolic side‑effects.
- Quetiapine - often chosen for its sedative effect, useful in insomnia‑related bipolar episodes.
- Haloperidol - a classic antipsychotic with high potency and higher EPS risk, but cheap and long‑standing.
- Aripiprazole - a partial dopamine agonist that can feel activating rather than sedating.
- Clozapine - reserved for treatment‑resistant schizophrenia; requires regular blood monitoring.
Side‑by‑side comparison table
| Medication | Typical daily dose | Efficacy (scale 1‑5) | Weight‑gain risk | Metabolic risk | EPS risk | Mean annual NHS cost (£) |
|---|---|---|---|---|---|---|
| Geodon | 20‑80mg (split doses) | 4 | Low | Low | Low‑moderate | ≈£800‑£1,200 |
| Risperidone | 1‑6mg | 4 | Low‑moderate | Low | Moderate | ≈£500‑£900 |
| Olanzapine | 5‑20mg | 5 | High | High | Low | ≈£1,200‑£1,800 |
| Quetiapine | 150‑800mg | 3‑4 | Moderate | Moderate | Low | ≈£600‑£1,000 |
| Haloperidol | 2‑20mg | 4 | Low | Low | High | ≈£300‑£500 |
| Aripiprazole | 10‑30mg | 4 | Low | Low | Low | ≈£1,000‑£1,500 |
| Clozapine | 100‑900mg | 5 | Low‑moderate | Moderate‑high | Low | ≈£2,000‑£2,800 |
Who benefits most from Geodon?
Geodon shines in three scenarios:
- Patients who need strong symptom control but are sensitive to weight gain - ziprasidone’s low‑weight‑gain risk is a standout.
- Individuals on multiple medications; Geodon is metabolised mainly by CYP3A4 and has fewer dangerous interactions than some alternatives.
- Those who can tolerate twice‑daily dosing; the short half‑life means split doses are needed for steady coverage.
Conversely, Geodon may not be ideal for:
- People with cardiac QT‑prolongation history - ziprasidone can lengthen the QT interval.
- Patients who struggle with pill burden; the requirement for meals high in fat to improve absorption adds complexity.
- Anyone seeking a once‑daily regimen; drugs like Risperidone or Olanzapine are simpler to schedule.
Practical considerations when switching
Switching antipsychotics isn’t a “stop‑and‑start” affair. Two common strategies are cross‑taper (gradually reduce the old drug while introducing the new) and direct switch (stop the first and start the second the same day). The choice depends on the current drug’s half‑life and the risk of relapse.
For Geodon, clinicians often start with a low 20mg dose taken with dinner, then add a morning dose if needed. Monitoring should include baseline ECG, fasting lipid panel and weight, then repeat after six weeks.
Cost and access in the UK
The NHS generally contracts Geodon as a specialty drug, requiring a prescription from a psychiatrist. Private prescriptions can cost up to £1,200 per year, while generic ziprasidone (available in limited pharmacies) drops the price to around £800. By contrast, Haloperidol is the cheapest option, but the side‑effect burden often outweighs the saving.
Bottom line
Geodon offers a solid middle ground: good efficacy with a low metabolic footprint, but you pay for twice‑daily dosing and need to watch heart rhythm. If weight gain is your biggest concern, ziprasidone beats Olanzapine and Quetiapine. If you need a once‑daily, low‑cost pill, Risperidone or Haloperidol may fit better.
Frequently Asked Questions
Can Geodon cause weight loss?
Weight loss isn’t a direct effect, but because ziprasidone rarely triggers appetite increase, many patients stay stable or lose a few pounds, especially if they pair the drug with a balanced diet.
Do I need to take Geodon with food?
Yes. Ziprasidone’s absorption jumps when taken with a meal containing at least 350kcal of fat. Skipping the meal can cut plasma levels by half.
How does Geodon compare to Clozapine for treatment‑resistant schizophrenia?
Clozapine remains the gold standard for treatment‑resistant cases because it works where other drugs fail. Geodon is useful when side‑effects are a bigger concern, but it doesn’t match Clozapine’s efficacy in refractory patients.
Is there a generic version of Geodon in the UK?
A generic ziprasidone formulation has been approved, but it’s stocked in fewer pharmacies than branded Geodon. Prices are lower, but you may need a specialist’s prescription to access it.
What monitoring is required while on Geodon?
Baseline ECG, fasting lipids, blood glucose, and weight are standard. Repeat the ECG after six weeks and then annually unless you have cardiac risk factors.
Can Geodon be used for bipolar depression?
Geodon is approved for bipolar mania, not depression. Some clinicians combine it with mood stabilisers for mixed episodes, but it’s not the first choice for pure depressive phases.
Greg DiMedio
October 12, 2025 AT 02:04Oh great, another table to make my coffee break feel productive.
Badal Patel
October 12, 2025 AT 23:13Behold! The illustrious comparison of ziprasidone, a marvel of modern psychopharmacology; yet, one must ponder the intricate tapestry of metabolic perils, the weighty specter of cardiac prolongation, and the ever‑present fiscal considerations-indeed, a saga worthy of scholarly discourse.
KIRAN nadarla
October 13, 2025 AT 21:26While the table is visually appealing, the lack of citation for the cost figures undermines its credibility. Moreover, the dosage column omits the necessary clarification that ziprasidone absorption is meal‑dependent. The EPS risk categorisation also conflates “low‑moderate” without a defined scale. A more rigorous approach would reference the primary literature and include confidence intervals. Such omissions are non‑trivial for clinicians making prescribing decisions.
Kara Guilbert
October 14, 2025 AT 16:53It’s unforgivable when patients are prescribed meds that silently add pounds while they’re already battling mental health issues; we have a moral duty to choose low‑weight options like ziprasidone over those that turn them into walking balloons.
Sonia Michelle
October 15, 2025 AT 15:06Considering the balance between efficacy and metabolic safety, Geodon emerges as a pragmatic choice for many. It offers solid symptom control without the heavy weight‑gain baggage of olanzapine, which aligns with a holistic view of patient wellbeing. In my experience, patients who avoid drastic weight changes tend to stay adherent longer, fostering a sense of agency over their treatment. Thus, the drug’s profile fits nicely into a patient‑centered philosophy that values quality of life as much as symptom remission.
Neil Collette
October 16, 2025 AT 10:33Listen, the moment you start cherry‑picking meds based solely on cost, you ignore the pharmacodynamic nuances that actually dictate therapeutic success. Ziprasidone’s affinity for 5‑HT2A receptors mitigates dopamine blockade side‑effects, a fact most casual prescribers overlook. Its QT‑prolongation potential, however, is non‑negotiable for patients with cardiac histories, and that’s why a blanket recommendation is reckless. You also need to factor in the meal‑fat requirement-otherwise plasma levels plummet and you’re just giving a placebo. Bottom line: any discussion that glosses over these details is intellectually dishonest.
James Lee
October 17, 2025 AT 08:46One might say that the very act of prescribing is a dance between art and chemistry, where ziprasidone waltzes gracefully between efficacy and a feather‑light metabolic footprint-though sometimes the choreography feels more like a clumsy two‑step.
Dennis Scholing
October 18, 2025 AT 18:06When evaluating antipsychotics, it is essential to adopt a systematic framework that accounts for multiple dimensions of patient care. First, efficacy should be quantified using standardized rating scales, ensuring that comparisons are evidence‑based rather than anecdotal. Second, side‑effect profiles, especially weight gain and metabolic disturbances, must be documented longitudinally because these factors heavily influence adherence. Third, extrapyramidal symptom risk remains a pivotal consideration for individuals with a history of movement disorders. Fourth, the pharmacokinetic requirements, such as the need for a high‑fat meal with ziprasidone, should be assessed for practicality in the patient’s daily routine. Fifth, cardiovascular safety, notably QT interval prolongation, mandates baseline and follow‑up ECG monitoring in at‑risk populations. Sixth, cost analysis should extend beyond the headline NHS price to incorporate indirect costs such as routine lab tests and potential hospitalizations. Seventh, drug‑interaction potential, especially via CYP3A4 pathways, warrants a thorough medication reconciliation. Eighth, patient preference for dosing frequency-once versus twice daily-can dramatically affect treatment continuity. Ninth, the availability of generic formulations may reduce financial barriers, though prescriber familiarity with brand‑specific adverse events remains crucial. Tenth, clinicians should weigh the benefits of newer agents against the long‑standing safety data of older drugs like haloperidol. Eleventh, shared decision‑making empowers patients, fostering adherence and satisfaction. Twelfth, clinicians must stay updated on emerging evidence, as comparative effectiveness studies continue to refine our understanding. Thirteenth, real‑world data from registries can reveal patterns not evident in controlled trials. Fourteenth, educational resources for patients about side‑effect monitoring improve early detection. Finally, a holistic approach that integrates medical, psychological, and social dimensions will ultimately yield the most favorable outcomes for individuals living with schizophrenia or bipolar disorder.
Kasey Lauren
October 19, 2025 AT 21:53Sounds like a solid option for anyone watching the scale!
joshua Dangerfield
October 20, 2025 AT 20:06I hear you; keeping weight stable while staying on effective meds can really boost confidence and overall mood.
Abhimanyu Singh Rathore
October 21, 2025 AT 15:33Wow-what a comprehensive breakdown! The table captures the nuances perfectly; it’s clear, concise, and incredibly helpful for clinicians and patients alike.
Stephen Lewis
October 22, 2025 AT 11:00In consideration of the presented data, it would be prudent to prioritize medications that align with individual metabolic risk profiles while also evaluating cost‑effectiveness within the NHS formulary constraints.
janvi patel
October 23, 2025 AT 09:13Nonetheless, efficacy alone should not dominate the decision‑making process.